The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival

American Journal of Hematology

Fecha de publicación: 3 November 2019

DOI: https://doi.org/10.1002/ajh.25671

Autores: Musa Yilmaz, Hagop Kantarjia, Xuemei Wang, Joseph D. Khoury, Farhad Ravandi, Jeffrey Jorgensen, Nicholas J. Short, Sanam Loghavi, Jorge Cortes, et al.

Background: he minimal or measurable residual disease (MRD) status following induction/consolidation chemotherapy is an important prognostic endpoint in adult patients with newly diagnosed acute lymphoblastic leukemia (ALL).